Raquel Castaneda
Family · Chandler, AZNPI 1568884310
Payments from drug & device makers
Across 590 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$817
- Corcept Therapeutics$790
- AstraZeneca$737
- Amgen$705
- Boehringer Ingelheim$672
- plus $6K from 37 others
What the payments were for
- Food & beverage$11,048100%
- Gifts$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,091 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 291 | $594,454 |
| JardianceEmpagliflozin | 233 | $325,630 |
| TrulicityDulaglutide | 145 | $299,280 |
| MounjaroTirzepatide | 99 | $208,916 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 97 | $146,586 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $99,935 |
| FarxigaDapagliflozin Propanediol | 70 | $90,375 |
| Tresiba Flextouch U-100Insulin Degludec | 93 | $88,451 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 64 | $78,610 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $34,497 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 192 | $34,246 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $33,108 |
| JanuviaSitagliptin Phosphate | 42 | $32,676 |
| SynjardyEmpagliflozin/Metformin Hcl | 18 | $32,261 |
| Humalog Kwikpen U-100Insulin Lispro | 90 | $30,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $817 | $619,303322 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $1,155 | $524,669296 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta | $672 | $402,226282 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $417 | $151,204110 claims |
| AstraZenecaFarxiga | $737 | $90,37570 claims |
| MerckJanuvia, Janumet Xr | $54 | $45,89653 claims |
| AmgenProlia | $705 | $29,22017 claims |
| Antares Pharma, Inc.Xyosted | $261 | $14,57712 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $328 | $7,078455 claims |
| AbbVieSynthroid | $207 | $5,72357 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Chandler
- Mia ChorneyChandler$79K
- Simon ParkinsonChandler$40K
- Anjanette KibbyChandler$21K
- Courtney BrzyckiChandler$14K
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.